Capai Regulatory News (CPAI)

THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND ("UK") PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

21 April 2026

 capAI plc (the "Company" and, together with its subsidiaries, the "Group" or "capAI")

AGM Trading & Strategic Update

capAI plc (LSE: CPAI, OTCQB: CPIQF) is pleased to provide a trading and strategic update ahead of its Annual General Meeting to be held today, Tuesday 21st April 2026.

The Company reports continued strong execution across its platform portfolio and is now entering a key inflection point, with multiple products transitioning from development into live user availability.

Near-Term Product Launches and Platform Momentum

· Game42 (Going Live): Game42, the generative game creation platform, is scheduled to go live this week. Game42 enables users to transform inputs ranging from short prompts to full-length books into interactive game experiences, significantly lowering the barrier to game development and supporting scalable user-generated content ecosystems.

· Creator42 / Movie42 (Going Live): Creator42, previously referenced in earlier communications, will launch this week under the name Movie42. The platform converts inputs-from a few lines to long-form narratives-into cinematic, trailer-style video outputs, positioning capAI within the rapidly expanding AI-driven content creation market.

· Author42 (Hard Launch): The Company is progressing toward the hard launch of Author42, its AI-native writing platform. Author42 now includes expanded capabilities across fiction and memoir writing, alongside advanced editing and refinement tools, supporting end-to-end content creation and complementing the broader Game42 and Movie42 ecosystem.

Transition to Deployment and Commercial Evaluation

With Game42 and Movie42 entering live deployment, capAI is transitioning into a phase focused on user adoption, iterative improvement and commercial evaluation. These launches represent a significant step toward validating product-market fit across multiple verticals.

capMedical - Longevity and Healthcare Initiatives

Further to the Company's previous RNS announcements, capAI continues to progress its capMedical initiative, including its focus on AI-enabled longevity and healthcare applications. A number of potential programmes in this area remain under active evaluation, with the Company applying its disciplined venture approach to assess both scientific and commercial viability before committing further resources.

Disciplined Venture Structure (LOA Framework)

The Company has to date operated a disciplined venture model, typically securing opportunities through Licence and Option Agreements (LOAs) that provide optionality to acquire or license technologies developed in collaboration with R42.

This structure enables capAI to explore and develop multiple initiatives at relatively low cost, while retaining the ability to capture significant upside through option-based access to successful projects. By deferring major capital commitments until technical and commercial viability is clearer, the Company maintains capital discipline and reduces downside risk. However, shareholders should note that there can be no guarantee that the Company will ultimately exercise any option to acquire or license such projects. Decisions to proceed are made selectively, based on technical progress, market potential and capital allocation considerations.

Outlook

The capAI board believes that the transition of multiple platforms into live availability, combined with a growing pipeline of opportunities under evaluation, positions capAI for its next phase of growth. The Company remains focused on disciplined execution, capital efficiency and the selective advancement of high-potential initiatives.

Further updates will be provided in due course.

Commenting, Professor Ronjon Nag, Executive Chairman of capAI, said:

"We are now seeing the transition of our core platforms from development into live deployment, which is a critical step in validating both their technical capability and commercial potential.

"At the same time, we continue to apply our disciplined venture approach to the evaluation of new opportunities, including in AI-enabled longevity and healthcare, where we believe there is significant long-term value creation potential. We look forward to providing further updates as these initiatives progress."

For the purposes of UK MAR, the person responsible for arranging release of this Announcement on behalf of capAI is Professor Ronjon Nag, Executive Chairman.

Enquiries

Company:

capAI plc hello@capaiplc.com

Broker:

AlbR Capital Limited Tel: +44 (0) 207 469 0930

Important Legal Information

The information contained in this Announcement is for background purposes only and does not purport to be full or complete, nor does this Announcement constitute or form part of any invitation or inducement to engage in investment activity. No reliance may be placed by any person for any purpose on the information contained in this Announcement or its accuracy, fairness or completeness. The contents of this Announcement are not to be construed as legal, financial or tax advice.

This Announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor.

This Announcement may include forward-looking statements, which are based on current expectations and projections about future events, including about the Group's operations, strategy, financial performance, development milestones, and the future prospects of its business divisions, including capMedia Inc, capMedical Inc, capMedia (UK) Ltd and capMedical (UK) Ltd. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "can have", "likely", "should", "would", "could" and any other words and terms of similar meaning or the negative thereof.

Forward-looking statements are based on current expectations and are subject to various risks and uncertainties that could cause actual outcomes to differ materially. These risks include, but are not limited to: successful execution of definitive agreements; regulatory approvals; development timelines; market acceptance; technological shifts; and broader economic conditions. No representation or warranty is made or will be made that any forward-looking statement will come to pass, and no assurance can be given that any forward-looking statement will prove accurate. Except as required by law, capAI undertakes no obligation to revise or update any forward-looking statement. The forward-looking statements in this Announcement speak only as at the date of this Announcement.